ArticleBMC women's health2025
Lessons from the scale-up of provider-administered and self-injection of DMPA-SC in Nigeria: a landscape assessment.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNigeria is the seventh-most populous country in the world. Its high fertility rate and unmet need for family planning contribute to the increasing population size. To reduce this gap, the Federal Government of Nigeria, in collaboration with Injectables Access Collaborative and other public and private sector players, introduced the subcutaneous depot medroxyprogesterone acetate (DMPA-SC) to the contraceptive method mix in 2017. We conducted an assessment to document the implementation experiences and best practices from the introduction of provider-administered and self-injection (SI) of DMPA-SC from the perspective of the government and implementing partners across states and federal governments levels from the supply-side. This is meant to serve as a learning resource to provide empirical evidence to help inform the DMPA-SC programming.
methodsA cross-sectional study design that employed a mixed-method approach to data collection was used for this assessment. Our methods included desk review of existing DMPA-SC implementation documents and key informant interviews conducted on 13 government and implementing partners across states and federal levels. Narrative summarization and graphical trend analysis were used for the presentation of information obtained from document review while Nvivo software (version 12) was used for the analysis of transcripts of the KIIs.
resultsThis assessment revealed a positive trend in the use of provider-administered and self-injection DMPA-SC from 2020 to 2023. This was supported by functional policies and guidelines. Implementing the Task Shifting and Task Sharing policy continuously; strengthening referral systems for provider-administered and self-injection DMPA-SC programme; and decentralising family planning services were suggested mechanisms for strengthening DMPA-SC programme implementation in Nigeria. However, funding gaps, human resource constraints, and weak coordination mechanisms impeded DMPA-SC implementation scale up.
conclusionThis assessment illustrates the influence of an enabling environment and stakeholder commitment on the positive trend in provider-administered and self-injection DMPA-SC uptake in Nigeria. Training service providers and improving funding through the use of innovative financing were recommended as levers for DMPA-SC programme sustainability and service scale-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.